

BARNES & THORNBURG**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Group Art
Unit: Not yet assigned

Application No.: 10/751,371

Filing Date: January 5, 2004

First Named Inventor:
Mandrea, Eugene

Title: *METHODS OF STIMULATING
IMMUNE RESPONSE IN VIRALLY
INFECTED INDIVIDUALS*


Attorney
Docket No.: 921880-95109

Examiner
Name: not yet assigned

P.O. Box 2786
Chicago, Illinois 60690-2786
(312) 357-1313

Certificate Under 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

on 3/14/04

(James B. Conte)

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sirs:

This statement is filed in the application identified above pursuant to 37 C.F.R. §1.97(b). No representation is intended that a complete search has been made of the prior art or that no better publications than listed on Forms PTO-1449 are available. A copy of each publication cited is provided herewith for review by the Examiner.


The filing of this Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in §1.56(b).

U.S. Ser. No.: 10/751,371

Attorney Docket No. 921880-95109

Please charge any deficiencies or credit any overpayments that might be due in connection with this Information Disclosure Statement to our Deposit Account No. 12-0913 with reference to our attorney docket number (921880-95109)

Respectfully submitted,



James B. Conte
Reg. No. 54,661

BARNES & THORNBURG
P.O. Box 2786
Chicago, Illinois 60690-2786
(312) 357-1313

Dated: 3/19/04

CHDS01 JCONTE 209006v1

FORM PTO/SB/08A
(REV. 10-96)

Substitute for form 1449A/PTO

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Complete if Known

O I P E JCT
MAR 22 2004
PATENT & TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Sheet 1 of 2

Application Number:	10/751,371
Filing Date:	January 5, 2004
First Named Inventor:	Mandrea, Eugene
Group Art Unit	not yet assigned
Examiner Name	not yet assigned.
Attorney Docket Number:	921880-95109

A U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
A.1	6,147,086		11-14-2000	Brenman	
A.2					
A.3					
A.4					
A.5					
A.6					
A.7					
A.8					
A.9					
A.10					
A.11					
A.12					
A.13					
A.14					

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
A.15						
A.16						
A.17						
A.18						
A.19						

EXAMINER


DATE CONSIDERED

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Send to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Sheet 2 of 2

Complete if Known

Application Number 10/751,371Filing Date January 5, 2004First Named Inventor Mandrea, EugeneGroup Art Unit unknownExaminer Name not yet assigned.Attorney Docket Number 921880-95109**B OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A.1	Arrese <i>et al.</i> , (2001) Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier. <i>J Cutan Pathol.</i> 28(3):131-4..	
	A.2	Bishop <i>et al.</i> , (2001) The immune response modifier resiquimod mimics CD40-induced B cell activation. <i>Cell Immunol.</i> 25;208(1):9-17.	q
	A.3	Dahl MV (2002) Imiquimod: a cytokine inducer. <i>J Am Acad Dermatol.</i> 47 (4 Suppl):S205-8.	
	A.4	Dockrell and, Kinghorn (2001) Imiquimod and resiquimod as novel immunomodulators. <i>J Antimicrob Chemother.</i> 48(6):751-5	
	A.5	Gibson SJ (2002) Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. <i>Cell Immunol.</i> 218(1-2):74-86.	
	A.6	Hemmi et al., (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. <i>Nat Immunol.</i> 3(2):196-200	
	A.7	O'Mahony et al., (2001) New patient-applied therapy for anogenital warts is rated favourably by patients. <i>Int J STD AIDS.</i> 12(9):565-70	
	A.8	Stanley MA. (2002) Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. <i>Clin Exp Dermatol.</i> 27(7):571-7.	
	A.9		
	A.10		
	A.11		
	A.12		
EXAMINER		DATE CONSIDERED	

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional)². Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.